ライフサイエンスコーパス: thrombopoietin receptor

1 at from mice lacking c-Mpl (c-Mpl(-/-)), the thrombopoietin receptor.

2 lity to mimic loss of TET2 with simultaneous thrombopoietin receptor activation.

3 ustained response off treatment (SROT) after thrombopoietin receptor agonist (TPO-RA) discontinuation

4 xamine the in vivo effects of eltrombopag, a thrombopoietin receptor agonist (TPO-RA), on platelet fu

5 Avatrombopag is an oral thrombopoietin receptor agonist (TPO-RA), taken with foo

6 The thrombopoietin receptor agonist eltrombopag has been sho

7 The oral thrombopoietin receptor agonist eltrombopag is approved

8 Eltrombopag (ELT) is a thrombopoietin receptor agonist reported to decrease lab

9 The thrombopoietin receptor agonist romiplostim could be an

10 We aimed to evaluate avatrombopag, a thrombopoietin receptor agonist that increases platelet

11 Romiplostim is a thrombopoietin receptor agonist that increases platelet

12 Eltrombopag is a small molecule thrombopoietin receptor agonist that might be a new opti

13 RE), we aimed to assess eltrombopag, an oral thrombopoietin receptor agonist, for thrombocytopenia (g

14 Eltrombopag, an oral thrombopoietin receptor agonist, increases platelet coun

15 Eltrombopag, an FDA-approved non-peptidyl thrombopoietin receptor agonist, is clinically used for

16 We tested whether eltrombopag, a thrombopoietin receptor agonist, might be effective in i

17 Eltrombopag, an oral thrombopoietin receptor agonist, stimulates platelet pro

18 de 3-kinase activator, in combination with a thrombopoietin-receptor agonist and the pyrimidoindole d

19 P were randomly assigned to receive the oral thrombopoietin-receptor agonist eltrombopag (30, 50, or

20 topenic disorders have been treated with the Thrombopoietin-receptor agonist Eltrombopag.

21 Eltrombopag is an oral, non-peptide, thrombopoietin-receptor agonist that stimulates thrombop

22 Eltrombopag is a new, orally active thrombopoietin-receptor agonist that stimulates thrombop

23 immunosuppression, eltrombopag, a synthetic thrombopoietin-receptor agonist, led to clinically signi

24 The effects of eltrombopag, a thrombopoietin-receptor agonist, on platelet function in

25 underlying etiology, include growth factors, thrombopoietin-receptor agonist, stem cell boost, transf

26 Eltrombopag is an oral thrombopoietin-receptor agonist.

27 Thrombopoietin receptor agonists (eltrombopag; romiplost

28 49.5%]), immune globulin (n=39 [18.2%]), and thrombopoietin receptor agonists (n=29 [13.6%]).

29 has changed with the advent of rituximab and thrombopoietin receptor agonists (TPO-RAs) as options fo

30 bundant clinical trial evidence, such as the thrombopoietin receptor agonists (TPO-RAs) rituximab and

31 Thrombopoietin receptor agonists (Tpo-RAs), which likely

32 The efficacy and safety of thrombopoietin receptor agonists (TRAs) in older patient

33 efficacy and safety, in particular, for the thrombopoietin receptor agonists and the occurrence of l

34 Thrombopoietin receptor agonists are reported to increas

35 ents respond to antithymocyte globulins, and thrombopoietin receptor agonists are under investigation

36 Thrombopoietin receptor agonists were recommended for ch

37 intravenous immunoglobulin within 2 weeks or thrombopoietin receptor agonists within 4 weeks before r

38 who achieved complete response for 1 year on thrombopoietin receptor agonists, half of the patients m

39 Tier 1 options (rituximab, thrombopoietin receptor agonists, low-dose corticosteroi

40 pecific therapies including corticosteroids, thrombopoietin receptor agonists, rituximab, and splenec

41 templating pregnancy while on treatment with thrombopoietin receptor agonists, rituximab, or mycophen

42 PURPOSE OF REVIEW: Thrombopoietin-receptor agonists (TPO-RAs) have been app

43 Stimulation of platelet production by thrombopoietin-receptor agonists (TPO-RAs) is an effecti

44 Combining an immunosuppressant therapy with thrombopoietin-receptor agonists may be a good strategy

45 combination of immunosuppressant therapy and thrombopoietin-receptor agonists that lasted for a media

46 ies of small peptides that bind to the human thrombopoietin receptor and compete with the binding of

47 More recently, activating mutations in the thrombopoietin receptor and in JAK2 exon 12 have been id

48 wn decreased megakaryocyte expression of the thrombopoietin receptor (c-mpl) in patients with polycyt

49 Here we describe a deletion mutant of the thrombopoietin receptor (c-mpl) that has completely lost

50 ematopoietic growth factors that bind to the thrombopoietin receptor, c-Mpl.

51 dy, we show that PF4 binds and activates the thrombopoietin receptor, cellular myeloproliferative leu

52 A thrombopoietin receptor derivative that brings the proli

53 growth factor receptor-1 (F36VFGFR1) and the thrombopoietin receptor (F36VMpl) induced a sustained ex

54 d to express a conditional derivative of the thrombopoietin receptor (F36Vmpl).

55 atic activating mutations in JAK2 and in the thrombopoietin receptor gene (MPL) in most patients with

56 al 5 to 10% have activating mutations in the thrombopoietin receptor gene (MPL).

57 a p.Lys39Asn amino acid substitution of the thrombopoietin receptor gene (p = 1.5 x 10(-11)).

58 a chemically induced dimerizer and modified thrombopoietin receptor has now allowed the expansion of

59 mutations of the erythropoietin receptor and thrombopoietin receptor have been identified in familial

60 e discovery of an activating mutation in the thrombopoietin receptor in JAK2-negative myelofibrosis a

61 lation of proteins and the expression of the thrombopoietin receptor in platelets from patients with

62 resultant mice were compared with a Mpl-/- (thrombopoietin receptor knockout) thrombocytopenic murin

63 expression of p21(Cip1), p27(Kip1), and the thrombopoietin receptor, known regulators of HSC self-re

64 This neoantigen directly activates the thrombopoietin receptor, leading to uncontrolled neoplas

65 Reduced expression of the thrombopoietin receptor MpI is characteristic of polycyt

66 However, expression of the platelet thrombopoietin receptor MpI was markedly reduced or abse

67 ia a pathogenic binding interaction with the thrombopoietin receptor MPL to induce MPNs.

68 Endocytosis of the thrombopoietin receptor Mpl was impaired in Dnm2-null pl

69 e demonstrated that mutant CALR binds to the thrombopoietin receptor MPL, and that the positive elect

70 59457 (SB), a nonpeptidyl hydrazone class of thrombopoietin receptor (Mpl) agonist, revealed toxicity

71 5R/R938Q induced spontaneous growth of Ba/F3-thrombopoietin receptor (MPL) but not of Ba/F3-human rec

72 Expression of the thrombopoietin receptor (Mpl) by platelets and megakaryo

73 We have reported defective thrombopoietin receptor (Mpl) protein expression in MPD

74 N-glycan-mediated activation of the thrombopoietin receptor (MPL) under pathological conditi

75 Mutations of thrombopoietin, the thrombopoietin receptor (MPL), and the erythropoietin re

76 sformation requires both mutated CRT and the thrombopoietin receptor (Mpl), but the molecular mechani

77 port here that amino acid substitutions in a thrombopoietin receptor (Mpl)--containing cell growth sw

78 ing JAK2 (JAK2), calreticulin (CALR), or the thrombopoietin receptor (MPL).

79 of mutant CALR to oncogenically activate the thrombopoietin receptor (MPL).

80 a marked reduction in the expression of the thrombopoietin receptor, Mpl, in polycythemia vera (PV)

81 The thrombopoietin receptor, Mpl, is a member of the cytokin

82 nner in 1 of 3 genes: JAK2, CALR, or MPL The thrombopoietin receptor, MPL, is the key cytokine recept

83 telets, and their precursors all express the thrombopoietin receptor, Mpl, on their cell surface.

84 iates the binding to, and activation of, the thrombopoietin receptor myeloproliferative leukemia prot

85 en OTT-MAL and an activating mutation of the thrombopoietin receptor myeloproliferative leukemia viru

86 tor, the erythropoietin receptor (EpoR), the thrombopoietin receptor, or the granulocyte colony-stimu

87 miR-28 exerts negative effects on thrombopoietin receptor signaling and platelet formation

88 scribed, somatic, activating mutation in the thrombopoietin receptor that is sensitive to down-stream

89 thymic stromal lymphopoietin, eotaxin-3, and thrombopoietin receptor to the RNA-induced silencing com

90 ombopag (EP) is a small-molecule, nonpeptide thrombopoietin receptor (TPO-R) agonist that has been ap

91 ts before (n = 10) and during treatment with thrombopoietin receptor (TPO-R) agonists (n = 9).

92 downstream signaling prematurely attenuating thrombopoietin receptor (TPO-R) signaling and constraini

93 Decreased expression of the thrombopoietin receptor (TPOR or MPL) on the cell surfac

94 Mutations in the MPL gene encoding the human thrombopoietin receptor (TpoR) drive sporadic and famili

95 Dimerization of the thrombopoietin receptor (TpoR) is necessary for receptor

96 The thrombopoietin receptor (TpoR) plays a central role in m

97 an agonist antibody to a cytokine receptor, Thrombopoietin receptor (TPOR) that effectively induces

98 ns participate in the activity states of the thrombopoietin receptor (TpoR), a type 1 cytokine recept

99 In the human thrombopoietin receptor (TpoR), a unique amphipathic RWQ

100 l, small-molecule, nonpeptide agonist of the thrombopoietin receptor (TpoR), being developed as a tre

101 stably and specifically interacting with the Thrombopoietin Receptor (TpoR), inducing its constitutiv

102 ors, namely the erythropoietin receptor, the thrombopoietin receptor (TpoR)/myeloproliferative leukem

103 ase 2 phosphorylation, initiated through the thrombopoietin receptor (TPOR/Mpl) activation, was affec

104 genic CALR mutants specifically activate the thrombopoietin receptor (TpoR/MPL).

105 ed amino acids, leading to activation of the thrombopoietin receptor (TpoR/MPL).

106 ngle transmembrane domain (TMD) of the human thrombopoietin receptor (TpoR/myeloproliferative leukemi

107 omerize with several other tagged receptors (thrombopoietin receptor, transforming growth factor beta

108 Although the thrombopoietin receptor was discovered in 1991 and throm

109 this idea, the signaling domain of Mpl (the thrombopoietin receptor) was targeted to the plasma memb